Chauvin sales rise thanks to foreign acquisitions:
This article was originally published in Clinica
Sales at French ophthalmology company Chauvin were up 68% to Fr 582 million ($120 million) in 1994 compared with the previous year. This includes sales from Smith & Nephew's (UK) ophthalmic division and Ankerpharm (Germany), which Chauvin purchased last year. Excluding these, sales were up 12.5% on 1993 figures. Consolidated profits remained flat at Fr 36 million. Excluding goodwill amortisation of the acquisitions, net profit rose 41% to Fr 52 million. Foreign sales increased during the year, with almost half the company's revenues coming from outside France, compared with just 20% in 1991. Chauvin expects a 5% growth in turnover in 1995.
You may also be interested in...
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.